Figure 4.

Diverse signaling molecule mutations are identified in CNL/aCML/unclassifiable/CMML. (A) The mosaic plot depicts the spectrum of different signaling molecule mutations in the cohort. (B) The pie chart depicts the frequencies of different signaling pathway mutations. (C) The graph depicts the VAFs of coexisting signaling pathway mutations showing co-occurrence pattern (red rectangle) and potential subclone pattern (blue rectangle). (D) Mean ± SEM of cell viability of Ba/F3 cells expressing CSF3R T618I with NRAS wild-type or mutant treated with gradient concentrations of indicated drugs for 72 hours (left). Mean ± SEM of cell viability of Ba/F3 cells expressing NRAS wild-type or mutant treated with a gradient concentration of indicated drugs for 72 hours (right). (E) Mean ± SEM of drug IC₅₀ of Ba/F3 cells expressing single or compound mutation treated with indicated drugs. Statistical significance was assessed using 1-way ANOVA and Kruskal-Wallis tests (*P < .05; **P < .01).